603127.SH
JOINN Laboratories (China) Co., Ltd.
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 46.39
−5.85%Sep 8, 2026, 13:51 UTC
On September 8, 2026, Joinn Laboratories held its 2026 interim results briefing, reporting H1 2026 revenue of 704 million yuan (up 5.27% year-on-year) and net profit attributable to shareholders of 748 million yuan (up 1126.8% year-on-year), driven largely by a 735 million yuan fair value gain on biological assets, while its core laboratory services business remained loss-making.
Source:Aug 28, 2026, 08:55 UTC
Joinn Laboratories released its 2026 interim report on August 28, reporting net profit attributable to shareholders of 748 million yuan, up 1126.8% year-on-year, and revenue of 704 million yuan, up 5.27% year-on-year.
Source:Jul 15, 2026, 01:50 UTC
Joinn Laboratories (06127) issued a profit alert, expecting a significant increase in net profit for the first half of 2026 due to a rise in biological asset market prices.